<DOC>
	<DOCNO>NCT01166282</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety adalimumab give subcutaneously every week ( eow ) compare placebo pediatric subject Enthesitis Related Arthritis ( ERA ) .</brief_summary>
	<brief_title>A Study Efficacy Safety Adalimumab Pediatric Subjects With Enthesitis Related Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Tendinopathy</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Diagnosis Enthesitis Related Arthritis ( ERA ) define International League Associations Rheumatology ( ILAR ) ; Disease activity define least 3 active joint evidence enthesitis least one location ; Inadequate response intolerance least one nonsteroidal antiinflammatory drug least one disease modify antirheumatic drug , either sulfasalazine methotrexate . Any ILAR Juvenile Idiopathic Arthritis ( JIA ) subtype ERA ; Psoriasis history psoriasis patient firstdegree relative ; Presence Immunoglobulin M ( IgM ) rheumatoid factor ; Presence systemic JIA ; History inflammatory bowel disease ; previous biologic therapy include antitumor necrosis factor ( antiTNF ) therapy potential impact pediatric ERA ; Infection ( ) require treatment IV antiinfectives within 30 day prior Baseline oral antiinfectives within 14 day prior Baseline .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>inflammatory back pain</keyword>
	<keyword>ankylose spondylitis</keyword>
	<keyword>sacroiliitis</keyword>
	<keyword>Juvenile Idiopathic Arthritis</keyword>
	<keyword>enthesitis</keyword>
	<keyword>arthritis</keyword>
</DOC>